Regulus Therapeutics

Regulus Therapeutics Inc.
Company typePublic
Nasdaq: RGLS
IndustryBiotechnology
FoundedSeptember 2007 (2007-09) (by Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals (NASDAQ:ISIS))
HeadquartersSan Diego, California, U.S.
Key people
ProductsmicroRNA therapeutics
Number of employees
30
Websiteregulusrx.com

Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals.

On June 25, 2025, two months after reporting that it had reached an agreement, Novartis announced the completion of its purchase of the company.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.